Long-term study of givinostat in people with Duchenne muscular dystrophy
Tests givinostat for long-term safety in people with Duchenne muscular dystrophy who were treated before.
Plain-language title generated from the registry record
Registry title: Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Key facts
- Where
- Leiden and Nijmegen, NetherlandsSee the 2 sites
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for boys and men with Duchenne muscular dystrophy who took part in an earlier givinostat study and are at least 6 years old. It tests givinostat over a long time.
- Age
- 6 years or older (the registry lists 7 years as the minimum age).
- Sex
- Male only.
- Disease stage
- Duchenne muscular dystrophy (DMD).
- Earlier treatment
- Must have taken part in an earlier givinostat study in DMD and attended its End of Study Visit. Or must have been screened in study DSC/14/2357/48, met its criteria, had a vastus lateralis muscle fat fraction of 5% or less or above 30%, and never been randomized. No medicine other than corticosteroids that could affect muscle strength within 3 months before joining. No other investigational drug now.
- Biomarker or test result
- Vastus lateralis muscle fat fraction by MRS of 5% or less, or above 30%, only for those screened but not randomized in study DSC/14/2357/48.
Main reasons for not taking part
- Another serious illness, or uncontrolled neurological or other body disease not related to DMD
- Heart failure (NYHA class III or IV), or a heart rhythm test (QTcF) above 450 msec
- Liver disease or impairment, or poor kidney function
- Platelets, white blood cells or hemoglobin below the normal limit, or triglycerides above 300 mg/dL (3.4 mmol/L) when fasting
- Sorbitol or fructose intolerance, or allergy to the study medicine
Read by machine on 9 November 2026.
Where in Netherlands
- Leiden University Medical Center LUMC, Albinusdreef 2Leiden, NetherlandsEnrolling by invitation
- Radboud university medical centreNijmegen, NetherlandsEnrolling by invitation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Italfarmaco
- Trial code
- NCT03373968
- Record updated
- 21 January 2026
- Original description
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.Read full original descriptionShow less
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been previously treated in one of the GIVINOSTAT studies.
Inclusion: Must have participated in one of the previous studies with GIVINOSTAT in DMD and have attended the End of Study Visit or must have been screened in study DSC/14/2357/48 and met:; all the inclusion criteria and none of the exclusion criteria,; had a baseline vastus lateralis muscle fat fraction (VL MFF) assessed by MRS in the range ≤5% or >30%, i.e. included in"off-target" group,; never been randomized because, the enrollment in the off target group was completed; Aged ≥6 years old; Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to localregulations); Subjects must be willing to use adequate contraception:; Contraceptive methods must since the previous GIVINOSTAT study through 3 months after the last dose of study drug, and include the following:; True abstinence (absence of any sexual intercourse), when in line with the preferred and usual lifestyle of the subject; Periodic abstinence (e.g. calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception; Condom with spermicide and the female partner must use an acceptable method of contraception, such as an oral,; transdermal, injectable or implanted steroid-basedcontraceptive, or a diaphragm or a barrier method of contraception in conjunction with spermicidal jelly such asfor example cervical cap with spermicide jelly.
Exclusion: Use of any current investigational drug other than Givinostat; Have presence of other clinically significant disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results; Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD; Have heart failure (New York Heart Association Class III or IV); Have a psychiatric illness/social situation rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures; Have any hypersensitivity to the components of study medication; Use of any pharmacologic treatment, other than corticosteroids, that might have had an effect on muscle strength or function within 3 months prior to be enrolled in this study (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed; Have platelets count, White Blood Cell and Hemoglobin at screening < Lower Limit of Normal (LLN)* (for abnormal screening laboratory test results (<LLN), the platelets count, White Blood Cell and Hemoglobin will be repeated once; if the repeat test result is still <LLN, then exclusionary); Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit* (for abnormal screening laboratory test results (>300 mg/dL), the triglycerides will be repeated once; if the repeat test result is still >300 mg/dL, then exclusionary); Have inadequate renal function, as defined by serum Cystatin C >2 x the upper limit of normal (ULN) at screening visit*. If the value is >2 x ULN, the serum Cystatin C will be repeated once; if the repeated test result is still >2 x ULN, the subject should be excluded); Have a current liver disease or impairment, including but not limited to an elevated total bilirubin* (i.e. > 1.5 x ULN), unless secondary to Gilbert disease or pattern consistent with Gilbert's; Have a baseline QTcF >450 msec, (as the mean of 3 consecutive readings 5 minutes apart) or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome); Have a sorbitol intolerance or sorbitol malabsorption or have the hereditary form of fructose intolerance; the Investigators to evaluate these exclusion criteria can use the laboratory results obtained within 5 months from V1, to allow the continuity of the treatment. It is worth noting, as soon as the site will receive the laboratory results done in screening/baseline (Visit 1) visit they will check the GIVINOSTAT dose and modify it as per protocol safety rules and/or dosage modifications rules.